Rezurock

(Belumosudil BID)

Phase 2Small molecule

KKadmon Corporation, LLC

Rezurock is one of 39 small molecule programs targeting Multiple Myeloma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaRecruiting

Multiple MyelomaPhase 2

Recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Empliciti

Bristol-Myers Squibb

Phase 3

45 2

Belamaf

GSK

Phase 3

39 3

Fludara

Sanofi

Phase 3

47 4

TALVEY

Johnson & Johnson

Phase 3

24 5

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 6

Biaxin

AbbVie

Phase 3

15 7

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 8

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

23 9

Elranatamab

Vepesid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

Multiple Myeloma

NCT06105554

Clinical

Trials by Indication[1]

Female2 trials

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

Completed·KKadmon, a Sanofi Company·Phase 1·NCT05918614·8 enrolled

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

Completed·KKadmon, a Sanofi Company·Phase 1·NCT05918588·32 enrolled

Oral1 trial

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

Completed·KKadmon, a Sanofi Company·Phase 1·NCT05918627·32 enrolled

Treatment1 trial

Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

Completed·KKadmon, a Sanofi Company·Phase 2·NCT05305989·23 enrolled

Multiple Myeloma1 trial

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06105554·36 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 16, 2021

REZUROCK

NDA NDA214783

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Belumosudil BID. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Belumosudil BID compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Belumosudil BID. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA214783). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Kadmon Corporation, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKadmon Corporation, LLC

Rezurock

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Female2 trials

Oral1 trial

Treatment1 trial

Multiple Myeloma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News